Breast Cancer

Recent Breast Cancer clinical practice guidelines, published in JCO. Includes access to additional tools and resources.
To develop guideline recommendations concerning optimal neoadjuvant therapy for breast cancer.
To update recommendations on appropriate use of breast cancer biomarker assay results to guide adjuvant endocrine and chemotherapy decisions in early-stage breast cancer.
To update recommendations of the American Society of Clinical Oncology (ASCO)-Ontario Health (Cancer Care Ontario [CCO]) adjuvant bone-modifying agents in breast cancer guideline.
The aim of this work is to update key recommendations of the ASCO guideline adaptation of the Cancer Care Ontario guideline on the selection of optimal adjuvant chemotherapy regimens for early breast cancer and adjuvant targeted therapy for breast cancer.
To provide recommendations on the best strategies for the management and on the best timing and treatment (surgical and radiotherapeutic) of the axilla for patients with early-stage breast cancer.
To update recommendations of the ASCO systemic therapy for hormone receptor (HR)-positive metastatic breast cancer (MBC) guideline.
This guideline updates recommendations of the ASCO guideline on chemotherapy and targeted therapy for patients with human epidermal growth factor receptor 2–negative metastatic breast cancer that is either endocrine-pretreated or hormone receptor–negative.
To update the American Society of Clinical Oncology endorsement of the Cancer Care Ontario recommendations on the Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer.
To update the ASCO guideline on pharmacologic interventions for breast cancer risk reduction and provide guidance on clinical issues that arise when deciding to use endocrine therapy for breast cancer risk reduction.
To update key recommendations of the American Society of Clinical Oncology/College of American Pathologists estrogen (ER) and progesterone receptor (PgR) testing in breast cancer guideline.
To develop recommendations concerning the management of male breast cancer.
To develop recommendations for management of patients with breast cancer (BC) with germ line mutations in BC susceptibility genes.

This site is intended for healthcare professionals in Europe and Japan only.

The selection of ASCO content on this site was made by the ASCO Publication and Education teams. Springer Healthcare selected the experts for interview. All content is made available solely for educational and informational purposes and personal use only.

© 2022 American Society of Clinical Oncology (ASCO®). All Rights Reserved.

This program is supported by an educational grant from Daiichi Sankyo and brought to you by Springer Healthcare | Contact Us | Privacy Policy

Before you go....

We'd love your feedback!

Your feedback will help guide us in the next phase of this program. Please take a few minutes (estimated 2 minutes) to answer the following 6 questions.